Last reviewed · How we verify
Peg-IFNα-2a
Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.
Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis B, Chronic hepatitis C, Certain malignancies (e.g., melanoma, some hematologic cancers).
At a glance
| Generic name | Peg-IFNα-2a |
|---|---|
| Also known as | peginterferon alfa-2a, pegylated interferon alpha 2a |
| Sponsor | Beijing 302 Hospital |
| Drug class | Interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology |
| Phase | FDA-approved |
Mechanism of action
Peg-IFNα-2a is a pegylated form of interferon alpha-2a that extends the drug's half-life and duration of action. It binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes, enhance natural killer cell activity, and promote apoptosis in infected or malignant cells. The pegylation allows for less frequent dosing while maintaining therapeutic efficacy.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Certain malignancies (e.g., melanoma, some hematologic cancers)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/psychiatric effects
- Thyroid dysfunction
- Injection site reactions
Key clinical trials
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection (PHASE3)
- Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants (PHASE3)
- Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants (PHASE2)
- Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C (PHASE3)
- A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 (PHASE4)
- Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients (NA)
- A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |